# MRD GATE RCC (NCT06005818)

> Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06005818
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: University of Alabama at Birmingham
- Conditions: Renal Cell Carcinoma
- Interventions: Pembrolizumab injection
- Enrollment: 100
- Primary outcome: Disease Free Survival (DFS) by Investigator's assessment as defined by RECIST 1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mrd-gate-rcc-nct06005818